FY2028 Earnings Forecast for PLX Issued By Zacks Research

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities researchers at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Protalix BioTherapeutics in a report issued on Thursday, May 14th. Zacks Research analyst J. Vandermosten expects that the company will post earnings per share of $0.01 for the year. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Protalix BioTherapeutics in a report on Thursday, March 19th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $12.00.

Protalix BioTherapeutics Price Performance

Shares of Protalix BioTherapeutics stock opened at $1.98 on Monday. The business has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.21. Protalix BioTherapeutics has a 1 year low of $1.32 and a 1 year high of $3.19. The company has a market capitalization of $159.53 million, a price-to-earnings ratio of -15.23 and a beta of -0.01.

Institutional Investors Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth $26,000. SG Americas Securities LLC acquired a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth $31,000. Bank of America Corp DE lifted its holdings in shares of Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after buying an additional 21,886 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth $34,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Protalix BioTherapeutics by 126.5% during the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after buying an additional 8,498 shares in the last quarter. Institutional investors and hedge funds own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.